PolyPid Ltd. (PYPD): Price and Financial Metrics
GET POWR RATINGS... FREE!
PYPD Stock Price Chart Interactive Chart >
PYPD Price/Volume Stats
| Current price | $0.53 | 52-week high | $6.90 |
| Prev. close | $0.56 | 52-week low | $0.50 |
| Day low | $0.50 | Volume | 34,932 |
| Day high | $0.58 | Avg. volume | 434,296 |
| 50-day MA | $0.75 | Dividend yield | N/A |
| 200-day MA | $2.27 | Market Cap | 10.44M |
PolyPid Ltd. (PYPD) Company Bio
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.
Latest PYPD News From Around the Web
Below are the latest news stories about POLYPID LTD that investors may wish to consider to help them evaluate PYPD as an investment opportunity.
PolyPid to Present at the Barclays Global Healthcare ConferencePETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023. Barclays Global Investor Conference: Presentation Date: Tuesday, March 14, 2023Presentation Time:4:35 PM Eastern Time Investors interested in meeting with PolyPid during th |
PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call TranscriptPolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript February 8, 2023 Operator: Greetings, and welcome to the PolyPid Fourth Quarter and Full Year 2022 Conference Call. . As a reminder, this call is recorded. And I would now like to introduce your host for today’s conference, Brian Ritchie from LifeSci Advisors. Mr. Ritchie, you may […] |
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsFollowing Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 2023 into Ongoing SHIELD II Trial, which will be Enriched with Approximately 550 Additional Patients to Complete Clinical Testing for Potential NDA Top-line Results from SHIELD II Trial Anticipated mid-2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 08, 2023 ( |
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and operational |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! |
PYPD Price Returns
| 1-mo | -27.40% |
| 3-mo | -29.33% |
| 6-mo | -54.11% |
| 1-year | -90.52% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -24.01% |
| 2022 | -87.85% |
| 2021 | -42.02% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...